76 related articles for article (PubMed ID: 16023854)
1. Radiological, pathological and surgical outcomes after neoadjuvant endocrine treatment in patients with ER-positive/HER2-negative breast cancer with a clinical high risk and a low-risk 70-gene signature.
van Olmen JP; Jacobs CF; Bartels SAL; Loo CE; Sanders J; Vrancken Peeters MTFD; Drukker CA; van Duijnhoven FH; Kok M
Breast; 2024 Jun; 75():103726. PubMed ID: 38599047
[TBL] [Abstract][Full Text] [Related]
2. Neoadjuvant treatment of breast cancer.
Thompson AM; Moulder-Thompson SL
Ann Oncol; 2012 Sep; 23 Suppl 10(Suppl 10):x231-6. PubMed ID: 22987968
[TBL] [Abstract][Full Text] [Related]
3. Aromatase inhibitor and tamoxifen use and the risk of venous thromboembolism in breast cancer survivors.
Xu X; Chlebowski RT; Shi J; Barac A; Haque R
Breast Cancer Res Treat; 2019 Apr; 174(3):785-794. PubMed ID: 30659431
[TBL] [Abstract][Full Text] [Related]
4. Estrogen receptor-beta mediates the protective effects of aromatase induction in the MMTV-Her-2/neu x aromatase double transgenic mice.
Nair HB; Perla RP; Kirma NB; Krishnegowda NK; Ganapathy M; Rajhans R; Nair SS; Saikumar P; Vadlamudi RK; Tekmal RR
Horm Cancer; 2012 Apr; 3(1-2):26-36. PubMed ID: 22006184
[TBL] [Abstract][Full Text] [Related]
5. Proliferation, steroid receptors and clinical/pathological response in breast cancer treated with letrozole.
Miller WR; White S; Dixon JM; Murray J; Renshaw L; Anderson TJ
Br J Cancer; 2006 Apr; 94(7):1051-6. PubMed ID: 16538221
[TBL] [Abstract][Full Text] [Related]
6. Are all aromatase inhibitors the same? A review of controlled clinical trials in breast cancer.
Berry J
Clin Ther; 2005 Nov; 27(11):1671-84. PubMed ID: 16368441
[TBL] [Abstract][Full Text] [Related]
7. The role of aromatase inhibitors as adjuvant therapy for early breast cancer in postmenopausal women.
Mouridsen HT; Robert NJ
Eur J Cancer; 2005 Aug; 41(12):1678-89. PubMed ID: 16098456
[TBL] [Abstract][Full Text] [Related]
8. Neoadjuvant use of endocrine therapy in breast cancer.
Macaskill EJ; Dixon JM
Breast J; 2007; 13(3):243-50. PubMed ID: 17461898
[TBL] [Abstract][Full Text] [Related]
9. Safely promoting breast-conserving surgery and preventing early relapses with an aromatase inhibitor.
Markopoulos C
Surg Oncol; 2008 Aug; 17(2):113-28. PubMed ID: 18178077
[TBL] [Abstract][Full Text] [Related]
10. Surgical issues surrounding use of aromatase inhibitors.
Dixon JM; Renshaw L; Murray J; Macaskill EJ; Young O; Miller WR
J Steroid Biochem Mol Biol; 2005 May; 95(1-5):97-103. PubMed ID: 16023854
[TBL] [Abstract][Full Text] [Related]
11. Using aromatase inhibitors in the neoadjuvant setting: evolution or revolution?
Freedman OC; Verma S; Clemons MJ
Cancer Treat Rev; 2005 Feb; 31(1):1-17. PubMed ID: 15707700
[TBL] [Abstract][Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
